VYNE Therapeutics Inc.VYNENASDAQ
Loading
EPS Growth Under PressureDecelerating
Percentile Rank60
3Y CAGR-16.5%
5Y CAGR+46.3%
Year-over-Year Change
Year-over-year earnings per share growth rate
3Y CAGR
-16.5%/yr
Annual compound
5Y CAGR
+46.3%/yr
Recent deceleration
Percentile
P60
Within normal range
vs 5Y Ago
6.7x
Strong expansion
Streak
2 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 34.04% |
| 2024 | 66.06% |
| 2023 | 73.99% |
| 2022 | 58.48% |
| 2021 | 81.92% |
| 2020 | 5.07% |
| 2019 | 12.55% |
| 2018 | -68.17% |
| 2017 | -118.65% |
| 2016 | -61.70% |